Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy
Status:
NOT_YET_RECRUITING
Trial end date:
2025-10-30
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, multicenter, double-blinded, placebo-controlled trial. Eighty-eight patients with primary membranous nephropathy (PMN) will be randomly divided into the intervention and control groups. The intervention group will be administered maximum tolerable dose of ACEI/ARB and finerenone 20 mg QD. Control patients will be administered maximum tolerable dose of ACEI/ARB and a placebo. The primary endpoint is the relative change in urinary protein content from baseline to 6 months.